JP6379113B2 - 免疫グロブリンｇの鼻腔内投与による中枢神経系障害の治療 - Google Patents

免疫グロブリンｇの鼻腔内投与による中枢神経系障害の治療 Download PDF

Info

Publication number
JP6379113B2
JP6379113B2 JP2015559285A JP2015559285A JP6379113B2 JP 6379113 B2 JP6379113 B2 JP 6379113B2 JP 2015559285 A JP2015559285 A JP 2015559285A JP 2015559285 A JP2015559285 A JP 2015559285A JP 6379113 B2 JP6379113 B2 JP 6379113B2
Authority
JP
Japan
Prior art keywords
igg
subject
pooled human
disorder
human igg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015559285A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512490A5 (enExample
JP2016512490A (ja
Inventor
ウィリアム エイチ． フライ
ウィリアム エイチ． フライ
リア ラナエ ブレシン ハンソン
リア ラナエ ブレシン ハンソン
シャロン ポクローピンスキ
シャロン ポクローピンスキ
フランシスコ エム． サード ローサ
フランシスコ エム． サード ローサ
Original Assignee
バクスアルタ インコーポレイテッド
バクスアルタ インコーポレイテッド
バクスアルタ ゲーエムベーハー
バクスアルタ ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バクスアルタ インコーポレイテッド, バクスアルタ インコーポレイテッド, バクスアルタ ゲーエムベーハー, バクスアルタ ゲーエムベーハー filed Critical バクスアルタ インコーポレイテッド
Publication of JP2016512490A publication Critical patent/JP2016512490A/ja
Publication of JP2016512490A5 publication Critical patent/JP2016512490A5/ja
Application granted granted Critical
Publication of JP6379113B2 publication Critical patent/JP6379113B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
JP2015559285A 2013-02-26 2014-02-25 免疫グロブリンｇの鼻腔内投与による中枢神経系障害の治療 Active JP6379113B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361769673P 2013-02-26 2013-02-26
US61/769,673 2013-02-26
US201361862814P 2013-08-06 2013-08-06
US61/862,814 2013-08-06
PCT/US2014/018426 WO2014134070A1 (en) 2013-02-26 2014-02-25 Treatment of central nervous system disorders by intranasal administration of immunoglobulin g

Publications (3)

Publication Number Publication Date
JP2016512490A JP2016512490A (ja) 2016-04-28
JP2016512490A5 JP2016512490A5 (enExample) 2017-04-27
JP6379113B2 true JP6379113B2 (ja) 2018-08-22

Family

ID=50424697

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015559285A Active JP6379113B2 (ja) 2013-02-26 2014-02-25 免疫グロブリンｇの鼻腔内投与による中枢神経系障害の治療

Country Status (13)

Country Link
US (5) US9556260B2 (enExample)
EP (2) EP2961426B1 (enExample)
JP (1) JP6379113B2 (enExample)
AU (2) AU2014223679B2 (enExample)
DK (1) DK2961426T3 (enExample)
ES (1) ES2759226T3 (enExample)
HR (1) HRP20192111T1 (enExample)
HU (1) HUE046752T2 (enExample)
LT (1) LT2961426T (enExample)
PL (1) PL2961426T3 (enExample)
PT (1) PT2961426T (enExample)
SI (1) SI2961426T1 (enExample)
WO (1) WO2014134070A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150100042A1 (en) * 2013-10-07 2015-04-09 Impel Neuropharma Inc. Muroid Family Nasal Device
US20170027963A1 (en) * 2014-04-10 2017-02-02 Patrick Crowley Delivery of non-steroidal agents to the brain via the nasal tract to treat neurological disorders
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
US11844859B2 (en) 2017-08-20 2023-12-19 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
WO2019038756A1 (en) 2017-08-20 2019-02-28 Solubest Ltd. DRY POWDER COMPOSITIONS FOR INTRANASAL DELIVERY
CA3127113A1 (en) 2019-01-30 2020-08-06 Dongxu Sun Anti-gal3 antibodies and uses thereof
WO2020163815A1 (en) * 2019-02-07 2020-08-13 Innomed Technologies, Inc. Ivig treatments for bell's palsy
US20230181027A1 (en) * 2019-06-28 2023-06-15 Mayo Foundation For Medical Education And Research Methods and materials for treating neuromyelitis optica spectrum diseases
EP4021409A2 (en) * 2019-08-13 2022-07-06 Altimmune Inc Therapeutic agent effectiveness and its route of administration
AU2021278935A1 (en) 2020-05-26 2022-12-08 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (enExample) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US5624898A (en) 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
EP0805696B1 (en) 1995-01-23 2000-03-15 Direct-Haler A/S An inhaler
BR0008650B1 (pt) 1999-03-03 2010-12-28 dispositivo de transmissão via nasal.
US6585957B1 (en) 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
US20070254889A1 (en) * 2001-04-23 2007-11-01 Lee-Way Jin Compounds and methods useful for rescuing cells from beta-amyloid toxicity and treatment of Alzheimer's disease
CA2462682A1 (en) 2001-10-04 2003-04-10 Protein Therapeutics, Inc. The use of gammaglobulin for the treatment of immune-mediated diseases
US20040101909A1 (en) 2002-08-20 2004-05-27 Hema-Quebec, 2535 Boul. Laurier, Ste-Foy, Quebec, Canada G1V 4M3 Purification of polyreactive autoantibodies and uses thereof
KR20070110087A (ko) 2005-02-23 2007-11-15 알자 코포레이션 중추신경계에 활성 약제의 비강 투여
US20090136505A1 (en) 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
JP5231810B2 (ja) * 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
WO2007106617A2 (en) * 2006-01-30 2007-09-20 Talecris Biotherapeutics, Inc. Method of treatment and prophylaxis of diseases related to amyloid deposition using igm
CN101410134A (zh) * 2006-02-15 2009-04-15 台拉维夫大学拉莫特 展示蛋白质a作为向脑部递送的抗体和免疫复合物的结合剂的丝状噬菌体
US9808509B2 (en) 2007-06-08 2017-11-07 Healthpartners Research Foundation Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system
ES2449577T3 (es) * 2008-02-29 2014-03-20 Baxter International Inc. Actividad anti-amiloide de la inmunoblogulina intravenosa (IVIG) in vitro
US8622993B2 (en) 2009-12-18 2014-01-07 Healthpartners Research Foundation Device and method for delivering therapeutic substances to the maxillary sinus of a patient
JP6078344B2 (ja) * 2010-02-04 2017-02-08 ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト 免疫グロブリン製剤
WO2011150284A2 (en) * 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide

Also Published As

Publication number Publication date
DK2961426T3 (da) 2019-12-02
AU2018260883A1 (en) 2018-11-29
SI2961426T1 (sl) 2020-01-31
AU2014223679B2 (en) 2018-11-29
PL2961426T3 (pl) 2020-02-28
US11851481B2 (en) 2023-12-26
US20210101967A1 (en) 2021-04-08
US20190055307A1 (en) 2019-02-21
EP2961426B1 (en) 2019-10-30
PT2961426T (pt) 2019-12-09
AU2018260883B2 (en) 2020-08-06
US10144776B2 (en) 2018-12-04
LT2961426T (lt) 2019-12-27
US20140242067A1 (en) 2014-08-28
EP3597220A1 (en) 2020-01-22
US20170044244A1 (en) 2017-02-16
EP2961426A1 (en) 2016-01-06
HUE046752T2 (hu) 2020-03-30
WO2014134070A1 (en) 2014-09-04
ES2759226T3 (es) 2020-05-08
US9556260B2 (en) 2017-01-31
HRP20192111T1 (hr) 2020-03-20
US20240117025A1 (en) 2024-04-11
US12503501B2 (en) 2025-12-23
JP2016512490A (ja) 2016-04-28
AU2014223679A1 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
JP6379113B2 (ja) 免疫グロブリンｇの鼻腔内投与による中枢神経系障害の治療
JP6424210B2 (ja) プールされた免疫グロブリンｇを用いたアルツハイマー病の亜集団の治療
JP7097874B2 (ja) リシルオキシダーゼ様２阻害剤の使用
Wu et al. Borneol-driven meningeal lymphatic drainage clears amyloid-β peptide to attenuate Alzheimer-like phenotype in mice
CN104619341A (zh) 脑信号蛋白-4d结合分子在促进中风后的神经发生中的用途
US20250188158A1 (en) Treatment of Parkinson's Disease
JP6928450B2 (ja) エンドセリンｂ受容体アゴニストを用いた、神経精神疾患を治療するための組成物及び方法
AU2024202756A1 (en) Treatment of central nervous system disorders by intranasal administration of immunoglobulin g
US20210403559A1 (en) Use of semaphorin-4d binding molecules for the treatment of rett syndrome
JP2020530846A (ja) 方法
HK40015677A (en) Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170224

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180705

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180730

R150 Certificate of patent or registration of utility model

Ref document number: 6379113

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250